Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07030309

MEGA STUDY - Multicenter Evaluation of Gastroschisis Anomaly Study

The purpose of this observational study is to evaluate selected epidemiological aspects of gastroschisis (GS) and factors affecting health outcomes of newborns with this diagnosis in a population of fetuses with gastroschisis. The main questions the study aims to answer are:

* Are there correlations between the parameters of ultrasound evaluation of the bowel with the condition of the newborn's bowel as assessed by the surgeon? * What is the prevalence of the different forms of GS (classification according to the methodology of Molik et al. 2002, Perrone et al. 2018)? * What is the incidence of perioperative and postoperative complications and other complications of the neonatal period? * What is the relationship between the form of the defect (simple GS vs complex GS) and feeding milestones - TFEF, TPN, TSEF, TSOF, TFOF? * What is the relationship between clinical parameters, diagnostic and therapeutic management, including method and timing of delivery, and final outcomes? Participants will not perform any active tasks or receive interventions as part of this study. Data will be collected passively from historical medical records including prenatal test results, details of pregnancy, delivery, and postnatal information on the newborn's treatment. The information collected will be anonymized. The study aims to collect information on prenatal diagnosis and neonatal outcomes, analyze factors affecting final results, and develop the most optimal management regimen for GS in Poland.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Górnośląskie Centrum Zdrowia Dziecka, Szpital Uniwersytecki ŚUM, Klinika Chirurgii Dziecięcej i Urologii Dziecięcej, Katowice, Poland

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A fetus with a diagnosis of gastroschisis;
  • Availability of prenatal, delivery and postnatal records (for hospital discharge, transfer to another facility or death).

Exclusion criteria

  • pregnancies terminated before the 22nd week of pregnancy

Treatment and study plan

Gastroschisis

Other

Gastroschisis (GS) is a congenital abdominal wall defect in which the intestine is located outside the abdominal cavity. The prevalence of the GS classifies it as a rare disease (ORPHA:2368) Pregnancy complicated by gastroschisis is associated with an increased risk of serious perinatal complications.

The presence of accompanying intestinal anomalies (atresia, necrosis, perforation, and volvulus), which qualifies the defect in the cGS (complex gastroschisis) group, as opposed to sGS (simple gastroschisis), where these anomalies are absent.

cGS is associated with significantly increased neonatal morbidity and mortality when compared to sGS.

Primary outcomes

  1. The prevalence of different forms of GS

    Time frame: During primary surgery

    The prevalence of different forms of GS: simple, complex

Secondary outcomes

  1. Agreement rate between prenatal and neonatal assessment of the bowel condition

    Time frame: Prenatal assessment - during every US examination up to the time of delivery; newborn's evaluation - during primary surgery

    Comparison of the prenatal ultrasound bowel condition and the newborn's bowel assessment by the surgeon

  2. Prevalence of necrotizing enterocolitis (NEC)

    Time frame: Up to 28 days after birth

    Diagnosis of necrotizing enterocolitis (NEC) is based on sudden onset of feeding intolerance, abdominal distention, bloody stools, and signs of sepsis (i.e., changes in the heart rate, respiratory rate, temperature, and blood pressure) in preterm infants, according to the Bell scale, which integrates the clinical and radiological manifestations.

  3. Prevalence of short bowel syndrome (SBS)

    Time frame: During primary surgery or reoperation

    Diagnosis of short bowel syndrome (SBS) is in case of loss of bowel length or function significantly enough to cause malabsorption, requiring lifelong parenteral support

  4. Prevalence of newborn sepsis

    Time frame: Up to 28 days after birth

    Newborn sepsis - an infection involving the bloodstream in infants under 28 days old. The clinical syndrome with symptomatology and laboratory findings consistent with a systemic inflammatory response to a multimodal infection caused by bacteria viruses, fungi potentially leading to multiple organ dysfunction, failure and even death within the first 28 days of life.

  5. Time to full enteral feeding (TFEF)

    Time frame: From date of birth until the first day when full enteral feeding is achieved, assessed up to 28 days after birth.

    Time to full enteral feeding (TFEF) - the time when neonates start to receive all of their prescribed nutrition as milk feeds

  6. Duration of the total parenteral nutrition (TPN)

    Time frame: From the first day of TPN initiation until the last day of TPN administration, assessed up to 28 days after birth.

    Total Parenteral Nutrition (TPN) - duration of parenteral nutrition, the time of intravenous feeding of nutritional products

  7. Time to start enteral feeding (TSEF)

    Time frame: From date of birth until the first day enteral feeding is initiated, assessed up to 14 days after birth.

    Time to start enteral feeding (TSEF) - the time when neonates start enteral nutrition

  8. Time to start oral feeding (TSOF)

    Time frame: From date of birth until the first day of oral feeding initiation, assessed up to 28 days after birth.

    Time to start oral feeding (TSOF)- the time when neonates start oral feeding

  9. Time to full oral feeding (TFOF)

    Time frame: From date of birth until the first day full oral feeding is achieved, assessed up to 28 days after birth.

    Time to full oral feeding (TFOF) - the time to achieve oral exclusive feeding, without using additional or alternative feeding methods (such as gavage or nasogastric tube)

  10. Lenght of hospital stay (LOS)

    Time frame: Time from the newborn's birth to discharge from the hospital, up to 28 days after birth

    Lenght of hospital stay (LOS) - duration of hospitalization - a clinical metric that measures the time elapsed between a patient's hospital admittance and discharge. For newborns - the time between the day of birth and its discharge

  11. Prevalence of modes of delivery

    Time frame: At delivery

    Mode of delivery - method of pregnancy termination: vaginal delivery or cesarean delivery

  12. Duration of pregnancy

    Time frame: At delivery

    Duration of pregnancy [days]

  13. Time to repair (primary surgery)

    Time frame: From date and time of birth until the start of the primary surgical repair, up to 28 days after birth

    Time to repair (primary surgery); even primary closure or SILO [hours]

  14. Time to closure abdominal wall defect

    Time frame: From date and time of birth until the completion of definitive abdominal wall defect closure, up to 28 days after birth

    Time to abdominal wall defect closure, even primary or secondary [hour]

  15. Prevalence of neonatal death

    Time frame: Up to 28 days after birth

    Neonatal death within the first 28 days of life

  16. Prevalence of intrauterine death

    Time frame: After 22 gestational weeks

    Intrauterine death after 22 gestational weeks

  17. Prevalence of gastroschis types by Perrone et al. 2018

    Time frame: During primary surgery, up to 28 days after birth

    Type A: ischemic bowel, significantly constricted at the ring without atresia Type B: ischemic bowel, significantly constricted at the ring (but viable) with an associated atresia Type C: ischemic bowel with a closing ring with nonviable external bowel (necrosis) with or without an associated atresia Type D: a completely closed defect with either a nubbin of exposed tissue or no external bowel

  18. GPS (gastroschisis prognostic score) score by Cowan et al. 2012

    Time frame: During primary surgery, up to 28 days after birth

    GPS (gastroschisis prognostic score) based on bowel appearance in newborns (within 6 hours of birth)

    I. Bowel matting:

    0 -none (normal bowel without inflammation)

    • mild (slight inflammation or with a visible plaque on the surface (mild bowel matting), always needs to expand (required widening) the abdominal wall defect during primary closure)
    • severe (moderate to massive inflammation with fibrous plaque (severe bowel matting) on the surface, stiffness of the intestinal wall EABL)

    II. Bowel atresia 0 - absent

    • - suspected
    • - present

    III. Bowel necrosis 0 - none

    • focal
    • - diffuse

    IV. Bowel perforation 0 - none 2 - present

  19. Prevalence of Adverse Ultrasound Signs (AUS)

    Time frame: During every prenatal ultrasound examination, up to the time of delivery

    US 0-no adverse ultrasound signs: normal, stable, and adequate for the gestational age look of EABL (extra-abdominal bowel loops): normal bowel wall (non-hyperechoic, without oedema or/and thickening), free-floating loops without dilatation; no IABL (intra abdominal bowel loops) dilatation; no gastric dilatation.

    US 1-any ultrasound-adverse signs or progression: hyperechoic bowel wall or/and oedema or/and thickening; EABL dilatation; lack of lumen of EABL (collapsed bowel), non-free-floating loops with/or without bowel dilatation; IABL dilatation; gastric dilatation.

  20. Prevalence of Fetal Growth Restriction (FGR)

    Time frame: Assessed throughout pregnancy, up to the time of delivery

    Fetal Growth Restriction (FGR) - "For early FGR (< 32 weeks), three solitary parameters (abdominal circumference (AC) < 3(rd) centile, estimated fetal weight (EFW) < 3(rd) centile and absent end-diastolic flow in the umbilical artery (UA)) and four contributory parameters (AC or EFW < 10(th) centile combined with a pulsatility index (PI) > 95(th) centile in either the UA or uterine artery) were agreed upon. For late FGR (≥ 32 weeks), two solitary parameters (AC or EFW < 3(rd) centile) and four contributory parameters (EFW or AC < 10(th) centile, AC or EFW crossing centiles by > two quartiles on growth charts and cerebroplacental ratio < 5(th) centile or UA-PI > 95(th) centile) were defined." Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, Silver RM, Wynia K, Ganzevoort W. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016 Sep;48(3):333-9. doi: 10.1002/uog.15884.

  21. Prevalence of Composite Intestinal Complications (CIC)

    Time frame: Up to 28 days after birth

    Composite Intestinal Complications (CIC) - intestinal complication (atresia, necrosis, perforation, volvulus) resulting from the definition of complex gastroschisis and peri-/post-operative complications in both forms (sGS and cGS) of defect (post-closure reoperation, adhesion-related bowel obstruction, bowel resection, Ileostomy/colostomy, the requirement to improve bowel anastomosis

  22. Prevalence of bowel matting

    Time frame: During primary surgery, up to 28 days after birth

    Bowel matting: slight inflammation or with a visible plaque on the surface (mild bowel matting), always needs to expand (required widening) the abdominal wall defect during primary closure or moderate to massive inflammation with fibrous plaque (severe bowel matting) on the surface, stiffness of the intestinal wall EABL

Sponsors and collaborators

Lead sponsor

ResearchSkills

Network

Registry information

Acronym: MEGA

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Jun 22, 2025
Registry last updated
Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.